InflaRx plunges on plans to halt studies into lead asset in rare skin disorder

1 day ago 1

Healthcare
On the Move

InflaRx (NASDAQ:IFRX) lost over half of its market cap in the premarket on Wednesday after the German biotech announced it would discontinue studies into its lead candidate, vilobelimab, against a rare skin disorder called pyoderma gangrenosum in reaction to interim results

Recommended For You

More Trending News

Read Entire Article

InflaRx plunges on plans to halt studies into lead asset in rare skin disorder

Recommended For You

More Trending News

Related

Meta partners with Anduril for XR Army headsets

The Supreme Court unanimously greenlights a $1.5 billion oil...

Disney adds more subscriber perks to its Disney+ and Hulu se...

Amazon forming new group to focus on 'breakthrough' consumer...

Fed Chair Jerome Powell meets with President Trump to discus...

CME Group, CF Benchmarks to launch crypto reference rates, i...

Nutrien plans new Pacific Northwest terminal to increase pot...

NG Energy International reports Q1 results

AmeraMex International GAAP EPS of $0.00, revenue of $4.58M

Toncoin falls 7% as Elon Musk refutes Telegram founder’s cla...

Amplify International Enhanced DividendIncome ETF declares $...

Amplify Natural Resources DividendIncome ETF declares $0.113...

Amplify YieldShares CWP Dividend & Option Income ETF declare...

Trump has inadvertently shown Europe it needs to build a ful...

CoTec Holdings Corp. reports Q1 results

Chevron to lay off nearly 800 workers in the Permian Basin

Who's next to join the trillion-dollar market club: WMT, JPM...

A former police chief, sentenced to 30 years in prison for f...

Enterprise stocks mixed after Salesforce's quarterly results...

Autonomous race heats up as Tesla's launch rattles Uber and ...

Trending

Popular

نشا برنج در گیلان

اینفوتابناک | سفرهای استانی شهید جمهور